Pegylated interferon-alpha-2a for the treatment of ocular surface squamous neoplasia

Ocular surface squamous neoplasia (OSSN) is the most common nonpigmented ocular surface neoplasm. Interferon-alpha (IFNα)-2b has been proved to be an effective immunotherapeutic agent to treat OSSN. We have used intralesional and topical (36 μg/ml) pegylated (peg) IFNα-2a to treat a recurrent surgic...

Descripción completa

Detalles Bibliográficos
Autores principales: Nuruddin, Murtuza, Roy, Soma Rani, Hoque, Fahmida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979401/
https://www.ncbi.nlm.nih.gov/pubmed/35388258
http://dx.doi.org/10.4103/ojo.ojo_146_21
_version_ 1784681168384294912
author Nuruddin, Murtuza
Roy, Soma Rani
Hoque, Fahmida
author_facet Nuruddin, Murtuza
Roy, Soma Rani
Hoque, Fahmida
author_sort Nuruddin, Murtuza
collection PubMed
description Ocular surface squamous neoplasia (OSSN) is the most common nonpigmented ocular surface neoplasm. Interferon-alpha (IFNα)-2b has been proved to be an effective immunotherapeutic agent to treat OSSN. We have used intralesional and topical (36 μg/ml) pegylated (peg) IFNα-2a to treat a recurrent surgically failed case of OSSN instead of IFNα-2b. In this case report, we have shared our initial experience with the novel use of peg-IFNα-2a to treat OSSN. According to our brief clinical experience, peg-IFNα-2a is nontoxic to ocular surface and has a promising role to treat OSSN.
format Online
Article
Text
id pubmed-8979401
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-89794012022-04-05 Pegylated interferon-alpha-2a for the treatment of ocular surface squamous neoplasia Nuruddin, Murtuza Roy, Soma Rani Hoque, Fahmida Oman J Ophthalmol Case Report Ocular surface squamous neoplasia (OSSN) is the most common nonpigmented ocular surface neoplasm. Interferon-alpha (IFNα)-2b has been proved to be an effective immunotherapeutic agent to treat OSSN. We have used intralesional and topical (36 μg/ml) pegylated (peg) IFNα-2a to treat a recurrent surgically failed case of OSSN instead of IFNα-2b. In this case report, we have shared our initial experience with the novel use of peg-IFNα-2a to treat OSSN. According to our brief clinical experience, peg-IFNα-2a is nontoxic to ocular surface and has a promising role to treat OSSN. Wolters Kluwer - Medknow 2022-03-02 /pmc/articles/PMC8979401/ /pubmed/35388258 http://dx.doi.org/10.4103/ojo.ojo_146_21 Text en Copyright: © 2022 Oman Ophthalmic Society https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Case Report
Nuruddin, Murtuza
Roy, Soma Rani
Hoque, Fahmida
Pegylated interferon-alpha-2a for the treatment of ocular surface squamous neoplasia
title Pegylated interferon-alpha-2a for the treatment of ocular surface squamous neoplasia
title_full Pegylated interferon-alpha-2a for the treatment of ocular surface squamous neoplasia
title_fullStr Pegylated interferon-alpha-2a for the treatment of ocular surface squamous neoplasia
title_full_unstemmed Pegylated interferon-alpha-2a for the treatment of ocular surface squamous neoplasia
title_short Pegylated interferon-alpha-2a for the treatment of ocular surface squamous neoplasia
title_sort pegylated interferon-alpha-2a for the treatment of ocular surface squamous neoplasia
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979401/
https://www.ncbi.nlm.nih.gov/pubmed/35388258
http://dx.doi.org/10.4103/ojo.ojo_146_21
work_keys_str_mv AT nuruddinmurtuza pegylatedinterferonalpha2aforthetreatmentofocularsurfacesquamousneoplasia
AT roysomarani pegylatedinterferonalpha2aforthetreatmentofocularsurfacesquamousneoplasia
AT hoquefahmida pegylatedinterferonalpha2aforthetreatmentofocularsurfacesquamousneoplasia

Ejemplares similares